We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

TDY:NYSETeledyne Technologies Incorporated Analysis

Data as of 2026-03-10 - not real-time

$659.45

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Teledyne Technologies (TDY) is trading at $659.45, comfortably above its 50‑day SMA ($615) but just shy of the 20‑day SMA ($667), confirming a bullish price trend despite a bearish MACD histogram. The RSI sits at 54, indicating neutral momentum, while the Fear & Greed Index shows "Extreme Greed," reflecting strong market optimism. Revenue growth of 7.3% YoY, solid gross margins (42.8%) and operating margins (20.6%) underpin the fundamentals, and forward earnings estimates lift the PE to a more attractive 25.7 versus the trailing 34.9. The stock enjoys a modest upside of about 6% to the DCF‑derived fair value and analyst median target of $700, supported by recent strategic moves such as the acquisition of DD‑Scientific and new product launches in thermal‑visible imaging and radar components.
The balance sheet shows a high debt‑to‑equity ratio (≈25) but ample operating cash flow ($1.19 B) and free cash flow ($0.69 B) to service obligations. With a beta below 1, volatility at 26% over 30 days, and decreasing volume, liquidity risk is moderate. Overall, TDY presents a blend of growth and value characteristics, making it a compelling buy‑to‑hold for investors comfortable with its leverage and looking to capture near‑term upside while maintaining exposure to its diversified tech‑defense portfolio.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Price above 50‑day SMA and below 20‑day SMA indicating bullish trend
  • Recent earnings beat and 7% price gain since report
  • Acquisition of DD‑Scientific adding growth potential

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Forward PE compression to 25.7 and analyst median target near $700
  • Sustained revenue growth and strong operating margins
  • New product launches expanding addressable markets

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • Robust cash flow generation offsetting high debt levels
  • Diversified exposure across defense, aerospace, and scientific instruments
  • Limited upside beyond fair‑value estimates and modest ROE

Key Metrics & Analysis

Financial Health

Revenue Growth7.30%
Profit Margin14.63%
P/E Ratio34.9
ROE8.93%
ROA4.92%
Debt/Equity25.13
P/B Ratio2.9
Op. Cash Flow$1.2B
Free Cash Flow$686.3M
Industry P/E37.2

Technical Analysis

TrendBullish
RSI53.9
Support$631.47
Resistance$693.38
MA 20$667.08
MA 50$615.06
MA 200$551.78
MACDBearish
VolumeDecreasing
Fear & Greed Index80.52

Valuation

Fair Value$227.53
Target Price$699.62
Upside/Downside6.09%
GradeFair
TypeBlend

Risk Assessment

Beta0.81
Volatility26.12%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.